News | Fragile X News Today
essential fatty acid levels | Fragile X News Today | illustration of news announcement| Fragile X News Today
essential fatty acid levels | Fragile X News Today | illustration of news announcement| Fragile X News Today
Children with Fragile X share traits with those with autism spectrum disorder, but show differences in brain network patterns, per a study.| Fragile X News Today
SPG601, an oral treatment for fragile X syndrome that's now in clinical testing, has been granted orphan drug status in the European Union.| Fragile X News Today
Fragile X Awareness Day and Awareness Month are returning this July with new advocacy and fundraising initiatives for fragile X syndrome.| Fragile X News Today
The FDA has granted orphan drug and rare pediatric disease designations to fragile X treatment KER-0193, Kaerus Biosciences said.| Fragile X News Today
Long-term treatment with ZYN002 cannabidiol gel eased symptoms of irritability in children and adolescents with fragile X syndrome, per trial data.| Fragile X News Today
Kaerus is planning a proof-of-concept Phase 2 trial for KER-0193 after its fragile X syndrome treatment was found safe in healthy adults.| Fragile X News Today
A single dose of Spinogenix’s investigational oral therapy SPG601 led to significant reductions in a measure of abnormal brain activity among men with fragile X syndrome, according to top-line results from a Phase 2a trial. Announced by Spinogenix in a company press release, the results from the placebo-controlled Phase 2a trial (NCT06413537) were also presented […] The post SPG601 found to reduce measure of abnormal brain activity in fragile X appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
The FDA granted fast track designation to Spinogenix's experimental oral therapy SPG601 to treat fragile X syndrome.| Fragile X News Today
Researchers in Kansas and California will investigate people with the FMR1 premutation who are at risk of developing fragile X-associated tremor/ataxia syndrome (FXTAS), a condition related to fragile X syndrome that develops late in life. The five-year project, supported by a $3.1-million grant from the National Institutes of Health, will study key motor, cognitive, and brain […] The post Researchers to study FXTAS risk in people with FMR1 premutation appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
A Phase 2 clinical trial to test MRM-3379, an experimental oral treatment for fragile X syndrome, is expected to launch in 2025. Mirum Pharmaceuticals announced the plan in a company press release reporting financial results and business updates. It didn’t provide details on the trial’s design or location. In October, Mirum acquired global rights to […] The post Mirum plans 2025 Phase 2 trial testing fragile X treatment appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
Zygel safely led to behavioral improvements among children with fragile X syndrome, including those likely to have severe disease.| Fragile X News Today
Findings from researchers in Canada and Maryland support further development of gene therapy for treating people with fragile X syndrome.| Fragile X News Today
The International Fragile X Premutation Registry, which aims to speed research into the impact of premutations, is enrolling participants.| Fragile X News Today
The Canadian government has cleared KGK Science's Phase 2a trial testing NM-1001, a psilocybin microdose therapy, in fragile X syndrome.| Fragile X News Today
Shionogi has acquired Tetra Therapeutics, the developer of the BPN14770 treatment candidate for fragile X syndrome and Alzheimer’s disease.| Fragile X News Today
Investigational therapy BPN14770 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of fragile X syndrome.| Fragile X News Today
Tetra Therapeutics’ investigational oral therapy BPN14770 safely and effectively improved cognitive function in men with fragile X syndrome.| Fragile X News Today
A U.S. study shows that repeated sampling of hair follicles in people with fragile X syndrome can be used to measure FMRP protein levels.| Fragile X News Today
Due to the variability of its symptoms, a conclusive diagnosis of fragile X syndrome can only be obtained with genetic testing.| Fragile X News Today
Recruitment of adults with fragile X syndrome to test NM-1001, a microdose of the psychedelic psilocybin is ongoing in Ontario, Canada.| Fragile X News Today
Read about the characteristic symptoms of fragile X syndrome, which range from developmental and behavioral problems to physical features.| Fragile X News Today
Children with fragile X syndrome have had problems with their academic performance and social interactions since the COVID-19 pandemic.| Fragile X News Today
Fragile X syndrome is caused by low to no levels of the FMRP protein, important for brain development, due to mutations in the FMR1 gene.| Fragile X News Today
Category archive page for News.| Fragile X News Today
Steve Bryson is a science writer for Fragile X News Today with a PhD in biochemistry. He covers the latest news and information on a variety of fragile X topics.| Fragile X News Today
Marisa Wexler is a senior science writer for Fragile X News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of fragile X topics.| Fragile X News Today
Tetra Therapeutics has amended the protocols of two ongoing clinical trials testing zatolmilast to improve access for fragile X patients.| Fragile X News Today
July is Fragile X Awareness Month, and this year, there are many ways to help build and spread knowledge about fragile X syndrome.| Fragile X News Today
The International Fragile X Conference in July will bring together patients, caregivers, and professionals to learn about fragile X research.| Fragile X News Today
The FDA has approved a Phase 2 trial to test SPG601, an oral treatment candidate, in men with fragile X syndrome.| Fragile X News Today
The LivJoy Foundation is funding a four-year postdoctoral fellowship for a scientist at USC who will study fragile X syndrome in females.| Fragile X News Today
A combination of ibudilast and gaboxadol was shown to normalize behavior and improve memory in a mouse model of fragile X syndrome.| Fragile X News Today
Blood levels of two proteins, known as MMP9 and APP, could serve as biomarkers for fragile X syndrome where genetic testing is not possible.| Fragile X News Today
Fragile X-causing mutations in FMR1 cause structural DNA changes that affect other genes necessary for nerve cell function, a study says.| Fragile X News Today
School age-girls with fragile X show significantly poorer cognitive function and academic performance relative to matched healthy girls.| Fragile X News Today
Sensory symptoms, including overreactions to stimuli, are very common among fragile X patients and affect their daily life, a study found.| Fragile X News Today
Learn about fragile X syndrome, the most common cause of inherited intellectual disability and autism spectrum disorders.| Fragile X News Today
